High-yield points
- Most common surgical lesion in children with drug-resistant focal epilepsy .
- ILAE classification:
- Type I is dyslamination only (Ia radial, Ib tangential, Ic both).
- Type II adds dysmorphic neurons (IIa), plus balloon cells in IIb.
- Type III accompanies another lesion (IIIa–d).
- The 2022 update adds mMCD, MOGHE and "no definite FCD", and recommends an integrated, multi-layered diagnosis .
- Genetics:
- Type II and hemimegalencephaly are mosaic mTORopathies: somatic MTOR, AKT3, PIK3CA or RHEB, or two-hit DEPDC5, NPRL2 or TSC1/2.
- Type I, mMCD and MOGHE are linked to somatic SLC35A2 instead .
- Imaging: look for thickening, gray–white blurring, FLAIR signal and the transmantle sign (type IIb) .
- Bottom-of-sulcus dysplasia is often missed at first. Use 3T, FDG-PET (hypometabolic in 99%) and postprocessing .
- Surgery: complete resection matters most. About 70% achieve a favorable outcome. The transmantle sign and BOSD predict an excellent outcome .
Landmark papers
- Blümcke et al., N Engl J Med 2017: European series of 9,523 epilepsy surgery resections. Malformations of cortical development were 19.8% of cases, FCD was the most common type, and 52.7% of FCD cases were in children .
- ILAE FCD classification update (Najm et al., Epilepsia 2022): consensus classification that adds mMCD, MOGHE and "no definite FCD" and recommends an integrated, multi-layered diagnosis .
Focal cortical dysplasia (FCD) is a localized malformation of cortical development. It is the most common lesion in children having epilepsy surgery: in a European series of 9,523 resections, malformations of cortical development made up 19.8% of cases, FCD was the most common type, and 52.7% of the FCD cases were in children . This topic covers the ILAE classification, the genetics and the imaging features.
ILAE classification
- 2011 three-tier scheme :
- Type I: isolated dyslamination of the neocortex in one or more lobes.
- Ia: radial (vertical) dyslamination, with abundant microcolumns.
- Ib: tangential (horizontal) dyslamination, with abnormal layering.
- Ic: both vertical and horizontal abnormalities .
- Type II: isolated lesion with dyslamination and dysmorphic neurons.
- IIa: dysmorphic neurons without balloon cells.
- IIb: dysmorphic neurons with balloon cells.
- Type III: dyslamination associated with another principal lesion.
- IIIa: with hippocampal sclerosis.
- IIIb: adjacent to an epilepsy-associated tumor.
- IIIc: adjacent to a vascular malformation.
- IIId: adjacent to a lesion acquired in early life, such as trauma, stroke or encephalitis.
- 2022 update :
- New categories:
- Mild malformations of cortical development (mMCD) with excessive heterotopic neurons in the white matter.
- MOGHE (mMCD with oligodendroglial hyperplasia in epilepsy).
- "No definite FCD on histopathology," for suspected cases whose findings fit no FCD type.
- Multi-layered diagnosis: the histopathologic subtype is integrated with genetic and imaging findings, including whether the lesion was MRI-positive and how it was found (visual review or postprocessing).
- Type I is the weak point: type Ib and Ic still lack a consistent clinicopathologic description, and type Ic became a "wastebasket" for clinically suspected FCD with no or very subtle MRI findings.
- Immunohistochemistry is recommended, for example NeuN, MAP2, vimentin, CD34 and OLIG2, to detect architectural abnormalities and subtypes.
Genetics: a brief update
- Type II is an mTORopathy:
- Brain somatic MTOR mutations: these activating mutations were the first proof that brain-only (somatic) mutations cause FCD II. They were found in 15.6% of patients with FCD II (12 of 77), and rapamycin suppressed seizures in a mouse model .
- Activators and repressors: gain-of-function somatic variants (AKT3, MTOR, PIK3CA) and inherited loss-of-function variants in GATOR1 genes (DEPDC5, NPRL2) and TSC1/2 produce a spectrum from FCD to hemimegalencephaly. Where the lesion falls on it depends on the timing and the progenitor cell involved. A cause was identified in 41% .
- Pediatric surgical cohort (80 children): a cause was found in 63% of FCD II and hemimegalencephaly cases. Gain-of-function variants in MTOR, AKT3, PIK3CA and RHEB, and germline, somatic or two-hit variants in DEPDC5, TSC1 and TSC2, occurred only in FCD II or hemimegalencephaly. Panel-negative FCD II still showed strong pS6 staining, so all FCD II appear to be mTORopathies. The pathogenic variants are carried by the dysmorphic neurons and balloon cells .
- Two-hit mechanism: a germline DEPDC5 variant plus a brain somatic second hit causes focal epilepsy with FCD. This explains why familial GATOR1 epilepsy can produce a focal lesion .
- Type I and mMCD are genetically distinct: they do not carry mTOR-pathway variants. About 30% have somatic loss-of-function variants in SLC35A2, a glycosylation gene .
- MOGHE: somatic SLC35A2 variants were found in 45% (9 of 20) of pediatric surgical cases, making SLC35A2 a genetic marker for MOGHE .
- Practical points:
- Testing resected tissue, paired with blood, can show germline risk, for example DEPDC5 with family recurrence and SUDEP reports .
- Variant detection depends on the density of abnormal cells in the sample .
- mTOR is a treatment target .
Imaging features
- Protocol: use a dedicated 3T epilepsy protocol built on 3D acquisitions (the ILAE HARNESS-MRI protocol). The ILAE also endorses computer-aided postprocessing .
- FCD type II, classic signs :
- Cortical thickening.
- Blurring of the gray–white junction.
- Increased T2/FLAIR signal in the lesion and the subcortical white matter.
- Abnormal gyration, including a cortical dimple.
- Transmantle sign: a linear or funnel-shaped band of T2/FLAIR signal running from the lesion toward the ventricle.
- First described in 18 patients presenting before age 20, with cytomegaly and balloon cells on histology .
- It points to type IIb: it was significantly more frequent in IIb (p = 0.003) .
- IIb is easier to see than IIa: in 118 proven cases, MRI was positive in 91% of IIb vs. 51% of IIa, and 21% were MRI-negative overall . Almost one-third of FCD II remain MRI-negative, sometimes because the imaging was inadequate .
- Bottom-of-sulcus dysplasia (BOSD) :
- Three cardinal features :
- focal cortical thickening deep in a sulcus;
- a tapering band of signal running toward the ventricle (the transmantle sign);
- an abnormal, sometimes puckered, gyral pattern.
- Series of 85 patients:
- Easy to miss: the first MRI missed the lesion in 68%. It was found on repeat MRI, FDG-PET or postprocessing.
- MRI features: gray–white blurring (100%), cortical thickening (91%), transmantle band (62%), increased cortical T1 signal (46%) and increased subcortical FLAIR signal (26%).
- FDG-PET: focal hypometabolism in 99%.
- Location: mostly frontal and pericentral.
- Genetics: pathogenic mTOR-pathway variants in 63%.
- Outcome: 86% of operated patients became seizure-free .
- The transmantle sign predicts a good outcome: 12 of 13 children with it became seizure-free after complete resection of the MRI and ECoG abnormality. This was better than in FCD without the sign (p = 0.04) .
- FCD type I is subtle: MRI is positive in 20–100% of cases across series, with the findings rarely specified. Pediatric series describe a subtle increase in white matter T2/FLAIR signal and reduced white matter volume in type Ia .
- MOGHE changes with age (25 children) :
- Subtype I: laminar T2/FLAIR hyperintensity at the corticomedullary junction (median age 2.6 years).
- Subtype II: reduced gray–white differentiation from increased signal in the adjacent white matter (median age 14.1 years).
- Subtype I converts to subtype II, probably through myelin maturation between ages 3 and 6.
- Postprocessing helps with subtle lesions:
- In 91 proven FCD II cases, morphometric analysis (MAP) detected 82% of type IIa lesions vs. 65% on visual review.
- Combining MAP with visual review found 98% of lesions .
Why it matters surgically
- Complete resection is the key modifiable factor:
- In a meta-analysis of MRI-detected FCD (35 studies, 1,353 patients), 70% had a favorable outcome.
- Complete resection was associated with a favorable outcome (RR 2.42), as was temporal location (RR 1.38).
- FCD histologic type and intracranial EEG use were not .
- Pathology matters:
- In the European cohort of 9,147 patients, FCD type I and mMCD had among the worst outcomes, with 50.0% free of disabling seizures at 2 years.
- Longer epilepsy duration reduced the chance of seizure freedom and of coming off drugs. Children were more often drug-free .
Related topics
- Hemimegalencephaly: the hemispheric mTORopathy.
- Epilepsy in TSC: a related mTOR-pathway cause.
- Extratemporal Epilepsy Surgery: how FCD is resected.
- Intracranial EEG: defining the dysplastic zone.
- Epilepsy Surgery Overview: FCD among surgical etiologies.
- Supratentorial Low-Grade Glioma and Glioneuronal Tumors: low-grade epilepsy-associated tumors.
- Normal Embryological Development of the Brain and Spine: the developmental step behind this lesion.
References
- Blumcke I, Spreafico R, Haaker G, et al. Histopathological findings in brain tissue obtained during epilepsy surgery. N Engl J Med 2017;377(17):1648–1656. doi:10.1056/NEJMoa1703784. PMID 29069555. verified
- Blümcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011;52(1):158–174. doi:10.1111/j.1528-1167.2010.02777.x. PMID 21219302. verified
- Najm I, Lal D, Alonso Vanegas M, et al. The ILAE consensus classification of focal cortical dysplasia: an update proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2022;63(8):1899–1919. doi:10.1111/epi.17301. PMID 35706131. verified
- Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 2015;21(4):395–400. doi:10.1038/nm.3824. PMID 25799227. verified
- D'Gama AM, Woodworth MB, Hossain AA, et al. Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias. Cell Rep 2017;21(13):3754–3766. doi:10.1016/j.celrep.2017.11.106. PMID 29281825. verified
- Baldassari S, Ribierre T, Marsan E, et al. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. Acta Neuropathol 2019;138(6):885–900. doi:10.1007/s00401-019-02061-5. PMID 31444548. verified
- Ribierre T, Deleuze C, Bacq A, et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest 2018;128(6):2452–2458. doi:10.1172/JCI99384. PMID 29708508. verified
- Bonduelle T, Hartlieb T, Baldassari S, et al. Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). Acta Neuropathol Commun 2021;9(1):3. doi:10.1186/s40478-020-01085-3. PMID 33407896. verified
- Barkovich AJ, Kuzniecky RI, Bollen AW, et al. Focal transmantle dysplasia: a specific malformation of cortical development. Neurology 1997;49(4):1148–1152. doi:10.1212/wnl.49.4.1148. PMID 9339707. verified
- Colombo N, Tassi L, Deleo F, et al. Focal cortical dysplasia type IIa and IIb: MRI aspects in 118 cases proven by histopathology. Neuroradiology 2012;54(10):1065–1077. doi:10.1007/s00234-012-1049-1. PMID 22695739. verified
- Hofman PA, Fitt GJ, Harvey AS, et al. Bottom-of-sulcus dysplasia: imaging features. AJR Am J Roentgenol 2011;196(4):881–885. doi:10.2214/AJR.10.4423. PMID 21427340. verified
- Macdonald-Laurs E, Warren AEL, Francis P, et al. The clinical, imaging, pathological and genetic landscape of bottom-of-sulcus dysplasia. Brain 2024;147(4):1264–1277. doi:10.1093/brain/awad379. PMID 37939785. verified
- Wang DD, Deans AE, Barkovich AJ, et al. Transmantle sign in focal cortical dysplasia: a unique radiological entity with excellent prognosis for seizure control. J Neurosurg 2013;118(2):337–344. doi:10.3171/2012.10.JNS12119. PMID 23216463. verified
- Hartlieb T, Winkler P, Coras R, et al. Age-related MR characteristics in mild malformation of cortical development with oligodendroglial hyperplasia and epilepsy (MOGHE). Epilepsy Behav 2019;91:68–74. doi:10.1016/j.yebeh.2018.07.009. PMID 30061008. verified
- Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: a consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia 2019;60(6):1054–1068. doi:10.1111/epi.15612. PMID 31135062. verified
- Wagner J, Weber B, Urbach H, et al. Morphometric MRI analysis improves detection of focal cortical dysplasia type II. Brain 2011;134(Pt 10):2844–2854. doi:10.1093/brain/awr204. PMID 21893591. verified
- Willard A, Antonic-Baker A, Chen Z, et al. Seizure outcome after surgery for MRI-diagnosed focal cortical dysplasia: a systematic review and meta-analysis. Neurology 2022;98(3):e236–e248. doi:10.1212/WNL.0000000000013066. PMID 34893558. verified
- Lamberink HJ, Otte WM, Blümcke I, et al. Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study. Lancet Neurol 2020;19(9):748–757. doi:10.1016/S1474-4422(20)30220-930220-9). PMID 32822635. verified
Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every number cited was checked against the PubMed abstract. The 2022 classification table (including the type Ic definition), the immunohistochemistry panel, the FCD type I imaging findings and the "almost one-third MRI-negative" statement were checked against the open-access full text of reference 3 (PMC9545778). Type III subtypes and the type I/II definitions come from the abstract of reference 2. The surgical section is a brief summary, not a full review of surgical technique. The figure is an original illustration.